Loading clinical trials...
Loading clinical trials...
A Single-arm, Multicenter, Prospective Phase II Clinical Study of Anlotinib Combined With Benmelstobart in the First-line Treatment of Advanced Pheochromocytoma/Paraganglioma
Conditions
Interventions
Anlotinib and Benmelstobart
Locations
1
China
Cancer Center, Sun Yat-sen University
Guangzhou, Guangdong, China
Start Date
May 1, 2025
Primary Completion Date
May 1, 2027
Completion Date
May 28, 2027
Last Updated
April 29, 2025
NCT03206060
NCT06503146
NCT04924075
NCT03050268
NCT06573723
NCT05702944
Lead Sponsor
Sun Yat-sen University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions